Rocket Science Health Validates Targeted Olfactory-cleft Deposition In Non-human Primates Ahead Of The 4th Nasal Formulation & Delivery Summit

As nan gait of modern supplier find accelerates, nan manufacture is progressively recognizing that a breakthrough molecule is only arsenic effective arsenic its expertise to scope nan target site. Nowhere is this situation much acute than successful treating Central Nervous System (CNS) and brain-related illnesses, wherever nan blood-brain obstruction remains a formidable obstacle to accepted delivery. Today, nan "how" of supplier transportation is becoming arsenic strategically captious arsenic nan "what," driving a displacement toward innovative routes of management - specified arsenic nan intranasal transportation of vaccines and therapeutics - to bypass systemic barriers and amended diligent outcomes.

Rocket Science Health (RSH) is astatine nan forefront of this shift, having precocious achieved a pivotal milestone: demonstrating that its proprietary instrumentality exertion successfully targets nan olfactory cleft successful non-human primates (NHP). Because nan olfactory cleft provides a unique, non-invasive "right-of-way" for direct-to-brain administration, this successful NHP information serves arsenic a captious span toward quality commercialization, validating nan device’s expertise to execute precise, reproducible dosing successful nan astir challenging regions of nan nasal anatomy. Rocket Science Health (RSH) precocious conducted this NHP study successful collaboration pinch ClearPoint Neuro astatine their ClearPoint Advanced Laboratories. RSH is pleased to denote successful results of its NHP-adapted instrumentality that preserves nan aforesaid halfway transportation exertion and targeting attack arsenic nan company’s quality instrumentality technology.

The information assessed anatomical fit, repeatable placement, and verified targeted deposition of a low-viscosity water-like tracer to nan olfactory region by endoscopic imaging. Three rhesus macaques completed 2 sedated sessions each, generating N = 12 nostril-session samples (50 µL per nostril per administration).

Key findings:

• Deposition to nan targeted olfactory region was confirmed successful each nostrils tested.
• Device placement was accordant and repeatable crossed subjects, pinch nary insertion guidance crossed study days.
• Deposited tracer remained visible successful nan targeted olfactory region astatine 10 minutes station transportation (time points beyond 10 minutes were not assessed).
• No nasopharyngeal drainage aliases backflow retired of nan chemoreceptor was observed astatine appraisal clip points.
• No device-related adverse events aliases observable acute nasal trauma were noted during fitting, placement, aliases delivery.

RSH’s instrumentality exertion is built astir 3 pillars: quality factors (fit, comfort, easiness of use), vantage constituent (positioning precocious successful nan nasal cavity to alteration targeted release), and fluidics (low-force, liquid watercourse delivery), pinch configurability crossed supplier volumes and viscosities. The institution reports U.S. patent protection spanning some fluidics creation and targeted transportation methods, supporting a combination-product commercialization pathway.

These findings align pinch nan attraction of nan upcoming 4th Nasal Formulation & Delivery Summit (May 19–21, 2026 | Boston, MA), which unites formulation, transportation and merchandise improvement leaders to beforehand scalable, translatable, and commercially viable intranasal therapies. Rocket Science Health is 1 of nan summit’s cardinal partners. On Conference Day Two astatine 10:00 am, they’ll beryllium exploring really “Device Technology Should Be Your First Decision, Not Your Last.” Expect to locomotion distant from this convention knowing why instrumentality exertion should beryllium considered early successful nan R&D process and which specifications are astir captious to your program’s success.

Dive into nan afloat convention schedule here.